{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-250756","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2025-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.289766+00:00","generated_at":"2026-05-17T02:12:04.153892+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"IN8bio presents INB-619 preclinical data at ACR showing deep B cell depletion with minimal cytokine release","bullets":["INB-619 achieved complete B cell depletion in SLE donor models, equivalent to FDA-approved blinatumomab and mosunetuzumab.","INB-619 showed minimal IL-6 secretion at concentrations far lower than marketed TCEs, suggesting reduced CRS risk.","INB-619 selectively expanded γδ T cells without activating αβ T cells, supporting a safer safety profile.","Data presented at 2025 ACR Convergence; INB-619 is a potential first-in-class pan-γδ T cell engager targeting CD19."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-250756","json":"https://secwatch.observer/filing/0001193125-25-250756.json","markdown":"https://secwatch.observer/filing/0001193125-25-250756.md","text":"https://secwatch.observer/filing/0001193125-25-250756.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000119312525250756/0001193125-25-250756-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000119312525250756/d65132d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:12:04.153892+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}